Showing results (271-280 of 322) with videos related to
Sort By:
Pageof 33
British Journal of Haematology|February 5, 2020
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet countsHaifa Kathrin Al-Ali, Martin Griesshammer, Lynda Foltz, et al.American Journal of Hematology|September 3, 2025
Triple A Plus (AAA+) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 PatientsAyalew Tefferi, Giuseppe G Loscocco, Lior Rokach, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2021
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory MyelofibrosisJohn Mascarenhas, Rami S Komrokji, Francesca Palandri, et al.Leukemia|March 9, 2018
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNetTiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, et al.NEJM Evidence|August 26, 2025
Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 RearrangementSrdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M Vannucchi, et al.Haematologica|April 23, 2016
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trialSrdan Verstovsek, Alessandro M Vannucchi, Martin Griesshammer, et al.American Journal of Hematology|March 31, 2012
Unraveling the genetic underpinnings of myeloproliferative neoplasms and understanding their effect on disease course and response to therapy: proceedings from the 6th International Post-ASH SymposiumOmar Abdel-Wahab, Animesh Pardanani, Olivier A Bernard, et al.Blood Advances|February 27, 2026
Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemiaHarinder Gill, Francesca Palandri, David M Ross, et al.Blood Advances|May 7, 2025
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosisDavid M Ross, Florian H Heidel, Andrew C Perkins, et al.Leukemia|August 21, 2020
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational studyAlessandro M Vannucchi, Benedetta Sordi, Alessandro Morettini, et al.Pageof 33